CAR T-Cell Therapy Shows Potential in Head and Neck Cancer – OncLive
OncLive |
CAR T-Cell Therapy Shows Potential in Head and Neck Cancer
OncLive Beyond hematologic malignancies, chimeric antigen receptor (CAR) T-cell therapy could have potential in solid tumors, such as head and neck cancer, according to early results of a clinical trial presented at the 2017 AACR Annual Meeting. Serum Marker IDs Likely Responders to CAR–T Therapy in Lymphoma |
